Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Managing Hyperkalaemia: Getting Patients to Optimal RAASi Therapy
Author(s): James Burton , Clara Bonanad Lozano , Aaron Wong , et al Start date: Jul 02, 2025
Join James Burton (University of Leicester, Leicester, UK), Clara Bonanad (University Clinical Hospital of Valencia, Valencia, ES), Aaron Wong (Princess of Wales Hospital, Bridgend, Wales, UK) and Anjay Rastogi (David Geffen School of Medicine UCLA, Los Angeles, US) for this live webinar designed to enhance clinical practice in the management of hyperkalaemia.The programme aims to provide… View more

Cardiovascular Renal Metabolic

Heart Failure
Advancements in Triglyceride-lowering Therapies
Author(s): , Added: 9 months ago
In this video series, recorded at ESC 2024 in London, Prof Gerald Watts (University of Western Australia, Perth, Australia) is joined by Prof Robert S Rosenson (Mount Sinai Icahn School of Medicine, New York, US) to discuss developments in triglyceride-lowering therapies.The faculty consider triglycerides as a risk factor for cardiovascular disease and explore the relationship between… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Tricuspid Regurgitation Therapy
Author(s): Qiuyu Martin Zhu , Natalia Berry Added: 1 year ago

Heart Failure
Ablation as First-line Therapy for Atrial Fibrillation.
Author(s): Jason G Andrade Added: 1 year ago

Electrophysiology & Arrhythmia
ACC 2025: The CardiAMP-HF Trial
Author(s): Amish Raval Added: 2 months ago
ACC 2025 - Principal results from autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF) show favourable safety outcomes, however, the study did not meet its primary efficacy outcome using 6 minute walking rests as 3rd F-S tier.Dr Amish Raval (UW Health University Hospital Interventional Cardiology Clinic, WI, US) joins us onsite at ACC to discuss the… View more

Heart Failure
Emerging Toxicities, Translational Research and Reverse Cardio-oncology
Author(s): Massimiliano Camilli , Luca Maggio , Lorenzo Tinti , et al Added: 3 months ago

CV Disease in Special Populations

Heart Failure
AHA 24 Late-Breaking Discussion: The ZODIAC Trial
Author(s): Harriette Van Spall , Kausik Ray Added: 7 months ago
AHA Conference 2024 — Key findings from the ZODIAC trial investigating the role of a decision support system in optimising lipid-lowering therapy for ACS patients.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Kausik Ray (Imperial College London, UK) to discuss the findings from the randomized controlled ZODIAC trial assessing decision support systems (DSS) in optimising… View more

Prevention & Chronic Conditions

MI/ACS
EHRA 25: The MORE-CRT MPP Trial
Author(s): Christophe Leclercq Added: 2 months ago
EHRA 2025 - Outcomes from cardiac resynchronization therapy (CRT) with MultiPoint pacing (MPP) to treat patients who are not responding to standard CRT show that MPP does not improve the conversion rate of non-responders to responders compared to standard CRT; however, a reduction in HF hospitalisation was seen in the group receiving MPP.Prof Christophe Leclercq (Centre Hospitalier Universitaire… View more

Electrophysiology & Arrhythmia
SCAI 25: Insights from the TRITAVI Registry
Author(s): Francesco Pelliccia Added: 1 month ago
SCAI 2025 - Insights from antiplatelet therapy after transcatheter aortic valve replacement (TAVR) show patients who received single antiplatelet treatment had significantly lower rates of overall six-month mortality, CV death and non-CV death compared to those treated with double antiplatelet treatment.Dr Francesco Pelliccia (Sapienza University of Rome, Rome, IT) joins us to discuss insights… View more

Anticoagulation

Intervention
Chelation Therapy in Post-MI Pts with Diabetes: TACT2
Author(s): Gervasio L Lamas Added: 1 year ago
ACC 24 - In this video, Dr Gervasio L Lamas (Mount Sinai Medical Center, US) joins us onsite to discuss the findings from the TACT2 study of chelation therapy in post-myocardial infarction patients with diabetes (NCT02733185).The Trial to Assess Chelation Therapy 2 (TACT2) study is a randomized, double blind factorial clinical trial, aiming to determine if chelation-based strategy increases the… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic